(Q35719848)

9 August 2017

title

A phase II trial of huperzine A in mild to moderate Alzheimer disease (English)

1 reference

9 August 2017

main subject

phase II clinical trial

0 references

Alzheimer's disease

0 references

author name string

M S Rafii

1

1 reference

9 August 2017

S Walsh

2

1 reference

9 August 2017

J T Little

3

1 reference

9 August 2017

K Behan

4

1 reference

9 August 2017

B Reynolds

5

1 reference

9 August 2017

C Ward

6

1 reference

9 August 2017

S Jin

7

1 reference

9 August 2017

R Thomas

8

1 reference

9 August 2017

P S Aisen

9

1 reference

9 August 2017

Alzheimer's Disease Cooperative Study

10

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 April 2011

1 reference

9 August 2017

1 reference

9 August 2017

volume

76

1 reference

9 August 2017

issue

16

1 reference

9 August 2017

page(s)

1389-1394

1 reference

High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

An update on huperzine A as a treatment for Alzheimer's disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Huperzine A regulates amyloid precursor protein processing via protein kinase C and mitogen-activated protein kinase pathways in neuroblastoma SK-N-SH cells over-expressing wild type human amyloid precursor protein 695.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Cholinesterase inhibitors for Alzheimer's disease

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Huperzine A, a potential therapeutic agent for dementia, reduces neuronal cell death caused by glutamate.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Identification of amino acid residues involved in the binding of Huperzine A to cholinesterases

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

A new rating scale for Alzheimer's disease.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Acute and chronic studies with the anticholinesterase Huperzine A: effect on central nervous system cholinergic parameters.

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Mechanism of inhibition of cholinesterases by huperzine A

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine

27 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

Tacrine-huperzine A hybrids (huprines): a new class of highly potent and selective acetylcholinesterase inhibitors of interest for the treatment of Alzheimer's disease

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3269774

[Anti-cholinesterase activity of huperzine A]

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21502597

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1212/WNL.0B013E318216EB7B

1 reference

release_62trh5gxy5hdxch5qlesgagf5a

9 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/62trh5gxy5hdxch5qlesgagf5a

mapped directly with Wikidata item

24 November 2022

based on heuristic

PMC publication ID

3269774

1 reference

9 August 2017

1 reference